CPRX - Catalyst Pharmaceuticals Inc Stock Price, Fair Value and News

$22.52+0.33 (+1.49%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

CPRX Price Action

Last 7 days

5.0%

Last 30 days

2.0%

Last 90 days

-1.1%

Trailing 12 Months

40.8%

CPRX RSI Chart

CPRX Valuation

Market Cap

2.7B

Price/Earnings (Trailing)

16.69

Price/Sales (Trailing)

5.56

EV/EBITDA

10.17

Price/Free Cashflow

11.43

CPRX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

CPRX Fundamentals

CPRX Revenue

Revenue (TTM)

491.7M

Rev. Growth (Yr)

28.26%

Rev. Growth (Qtr)

10.2%

CPRX Earnings

Earnings (TTM)

163.9M

Earnings Growth (Yr)

60.53%

Earnings Growth (Qtr)

27.46%

CPRX Profitability

EBT Margin

43.98%

Return on Equity

22.52%

Return on Assets

19.25%

Free Cashflow Yield

8.75%

CPRX Investor Care

Shares Dilution (1Y)

11.88%

Diluted EPS (TTM)

1.31

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	411.3M	434.5M	460.5M	491.7M
2023	256.5M	302.9M	348.4M	398.2M
2022	153.7M	170.5M	191.8M	214.2M
2021	120.1M	126.9M	133.5M	140.8M
2020	119.0M	119.8M	118.2M	119.1M
2019	36.6M	54.6M	72.7M	102.3M
2018	0	0	0	18.5M
2010	0	0	0	489.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

CEO	Mr. Patrick J. McEnany
WEBSITE	catalystpharma.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	82

Catalyst Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Catalyst Pharmaceuticals Inc? What does CPRX stand for in stocks?

CPRX is the stock ticker symbol of Catalyst Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Catalyst Pharmaceuticals Inc (CPRX)?

As of Thu Apr 17 2025, market cap of Catalyst Pharmaceuticals Inc is 2.74 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CPRX stock?

You can check CPRX's fair value in chart for subscribers.

Is Catalyst Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether CPRX is over valued or under valued. Whether Catalyst Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Catalyst Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CPRX.

What is Catalyst Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 17 2025, CPRX's PE ratio (Price to Earnings) is 16.69 and Price to Sales (PS) ratio is 5.56. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CPRX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Catalyst Pharmaceuticals Inc's stock?

In the past 10 years, Catalyst Pharmaceuticals Inc has provided 0.172 (multiply by 100 for percentage) rate of return.